Reports
Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.
Global Glaucoma Therapeutics Market: By Drug Class: Prostaglandin Analogs, Beta Blockers, Alpha Adrenergic Agonists, Carbonic Anhydrase Inhibitors, Others; By Indication; By End Use; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics; Competitive Landscape; Industry Events and Developments
Global Glaucoma Therapeutics Market Outlook
The global market for glaucoma therapeutics reached a value of about USD 7.24 billion in 2021. The industry is further expected to grow at a CAGR of about 6.20% in the forecast period of 2022-2027 to reach a value of around USD 10.39 billion by 2027.
North America to be Among the Significant Regional Markets for Glaucoma Therapeutics
North America is expected to be one of the leading regions in the glaucoma therapeutics market owing to high per capita expenditure on healthcare. Major players operating in the market have made a series of strategic acquisitions, contributing to their market share. Further, the increase in the geriatric population, rise in awareness about glaucoma, availability of reimbursements, and well-established health care infrastructure are the other factors driving the market growth in North America.
Europe and the Asia Pacific to Witness Significant Growth
The glaucoma therapeutics market in Europe is expected to increase due to favourable reimbursement policies during the forecast period. Factors contributing to the growth of the market in the region include stronger emphasis by federal governments on improving healthcare facilities and a rise in awareness among the population. On the other hand, the Asia Pacific would showcase the highest growth, fuelled by the increasing ageing population, especially in Japan and China, which require these therapeutics.
Market Segmentations
Various therapy options for primary open-angle (POA) and primary angle-closure (PAC) glaucoma are referred to as glaucoma therapeutics. The condition is marked by structural alterations in the optic nerves, resulting in vision loss and blindness. Topical eye drops, which include beta-blockers, prostaglandin analogues, cholinergic, carbonic anhydrase inhibitors, and alpha-adrenergic agonists, can treat glaucoma.
By drug class, the market includes:
- Prostaglandin Analogues
- Beta-Blockers
- Alpha Adrenergic Agonists
- Carbonic Anhydrase Inhibitors
- Combination Drugs
- Others
Based on indication, the market is divided into:
- Open-Angle Glaucoma
- Angle Closure Glaucoma
- Others
The end-uses of the market are:
- Hospitals
- Ophthalmic Clinics
- Ambulatory Surgery Centres
- Others
The regional markets for the glaucoma therapeutics market can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
Increasing Prevalence of Glaucoma Propelling the Market Growth
One of the major factors driving the market's growth is the rising prevalence of glaucoma across the globe. Glaucoma is quite common among diabetic patients and people with additional visual problems, such as age-related macular degeneration (AMD), cataracts, and dry eye. Following this, the growing geriatric population, which is more vulnerable to such illnesses, propels the market growth. An increase in awareness of glaucoma, medical coverage of glaucoma patients and demand for combination glaucoma drugs are some of the significant trends that can be seen in the global glaucoma therapeutics industry. The industry is also being driven by rising health consciousness among the public and a growing preference for laser glaucoma surgery.
In addition, the invention of unique combination dugs is a growth-stimulating factor. Anti-glaucoma medicines and prostaglandin analogues are being developed by pharmaceutical companies in combination with two or more drugs to lower excessive IOP levels. Other factors, such as the introduction of better glaucoma diagnostic techniques and improvements in healthcare infrastructure, are expected to fuel the market growth further.
Key Players in the Global Market for Glaucoma Therapeutics
The report gives a detailed analysis of the following key players in the global glaucoma therapeutics market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Aerie Pharmaceuticals Inc.
- Bausch & Lomb Incorporated
- Inotek Pharmaceuticals Corp.
- SIFI S.p.A
- Viatris Inc.
- Teva Pharmaceutical Industries Ltd.
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Region
7 Industry Opportunities and Challenges
8 Global Glaucoma Therapeutics Market Analysis
8.1 Key Industry Highlights
8.2 Global Glaucoma Therapeutics Historical Market (2017-2021)
8.3 Global Glaucoma Therapeutics Market Forecast (2022-2027)
8.4 Global Glaucoma Therapeutics Market by Drug Class
8.4.1 Prostaglandin Analogs
8.4.1.1 Market Share
8.4.1.2 Historical Trend (2017-2021)
8.4.1.3 Forecast Trend (2022-2027)
8.4.2 Beta Blockers
8.4.2.1 Market Share
8.4.2.2 Historical Trend (2017-2021)
8.4.2.3 Forecast Trend (2022-2027)
8.4.3 Alpha Adrenergic Agonists
8.4.3.1 Market Share
8.4.3.2 Historical Trend (2017-2021)
8.4.3.3 Forecast Trend (2022-2027)
8.4.4 Carbonic Anhydrase Inhibitors
8.4.4.1 Market Share
8.4.4.2 Historical Trend (2017-2021)
8.4.4.3 Forecast Trend (2022-2027)
8.4.5 Combination Drugs
8.4.5.1 Market Share
8.4.5.2 Historical Trend (2017-2021)
8.4.5.3 Forecast Trend (2022-2027)
8.4.6 Others
8.5 Global Glaucoma Therapeutics Market by Indication
8.5.1 Open Angle Glaucoma
8.5.1.1 Market Share
8.5.1.2 Historical Trend (2017-2021)
8.5.1.3 Forecast Trend (2022-2027)
8.5.2 Angle Closure Glaucoma
8.5.2.1 Market Share
8.5.2.2 Historical Trend (2017-2021)
8.5.2.3 Forecast Trend (2022-2027)
8.5.3 Others
8.6 Global Glaucoma Therapeutics Market by End Use
8.6.1 Hospitals
8.6.1.1 Market Share
8.6.1.2 Historical Trend (2017-2021)
8.6.1.3 Forecast Trend (2022-2027)
8.6.2 Ophthalmic Clinics
8.6.2.1 Market Share
8.6.2.2 Historical Trend (2017-2021)
8.6.2.3 Forecast Trend (2022-2027)
8.6.3 Ambulatory Surgery Centres
8.6.3.1 Market Share
8.6.3.2 Historical Trend (2017-2021)
8.6.3.3 Forecast Trend (2022-2027)
8.6.4 Others
8.7 Global Glaucoma Therapeutics Market by Region
8.7.1 Market Share
8.7.1.1 North America
8.7.1.2 Europe
8.7.1.3 Asia Pacific
8.7.1.4 Latin America
8.7.1.5 Middle East and Africa
9 Regional Analysis
9.1 North America
9.1.1 Historical Trend (2017-2021)
9.1.2 Forecast Trend (2022-2027)
9.1.3 Breakup by Country
9.1.3.1 United States of America
9.1.3.2 Canada
9.2 Europe
9.2.1 Historical Trend (2017-2021)
9.2.2 Forecast Trend (2022-2027)
9.2.3 Breakup by Country
9.2.3.1 United Kingdom
9.2.3.2 Germany
9.2.3.3 France
9.2.3.4 Italy
9.2.3.5 Others
9.3 Asia Pacific
9.3.1 Historical Trend (2017-2021)
9.3.2 Forecast Trend (2022-2027)
9.3.3 Breakup by Country
9.3.3.1 China
9.3.3.2 Japan
9.3.3.3 India
9.3.3.4 ASEAN
9.3.3.5 Australia
9.3.3.6 Others
9.4 Latin America
9.4.1 Historical Trend (2017-2021)
9.4.2 Forecast Trend (2022-2027)
9.4.3 Breakup by Country
9.4.3.1 Brazil
9.4.3.2 Argentina
9.4.3.3 Mexico
9.4.3.4 Others
9.5 Middle East and Africa
9.5.1 Historical Trend (2017-2021)
9.5.2 Forecast Trend (2022-2027)
9.5.3 Breakup by Country
9.5.3.1 Saudi Arabia
9.5.3.2 United Arab Emirates
9.5.3.3 Nigeria
9.5.3.4 South Africa
9.5.3.5 Others
10 Market Dynamics
10.1 SWOT Analysis
10.1.1 Strengths
10.1.2 Weaknesses
10.1.3 Opportunities
10.1.4 Threats
10.2 Porter’s Five Forces Analysis
10.2.1 Supplier’s Power
10.2.2 Buyer’s Power
10.2.3 Threat of New Entrants
10.2.4 Degree of Rivalry
10.2.5 Threat of Substitutes
10.3 Key Indicators for Demand
10.4 Key Indicators for Price
11 Competitive Landscape
11.1 Market Structure
11.2 Company Profiles
11.2.1 Aerie Pharmaceuticals Inc.
11.2.1.1 Company Overview
11.2.1.2 Product Portfolio
11.2.1.3 Demographic Reach and Achievements
11.2.1.4 Certifications
11.2.2 Bausch & Lomb Incorporated
11.2.2.1 Company Overview
11.2.2.2 Product Portfolio
11.2.2.3 Demographic Reach and Achievements
11.2.2.4 Certifications
11.2.3 Inotek Pharmaceuticals Corp.
11.2.3.1 Company Overview
11.2.3.2 Product Portfolio
11.2.3.3 Demographic Reach and Achievements
11.2.3.4 Certifications
11.2.4 SIFI S.p.A
11.2.4.1 Company Overview
11.2.4.2 Product Portfolio
11.2.4.3 Demographic Reach and Achievements
11.2.4.4 Certifications
11.2.5 Viatris Inc.
11.2.5.1 Company Overview
11.2.5.2 Product Portfolio
11.2.5.3 Demographic Reach and Achievements
11.2.5.4 Certifications
11.2.6 Teva Pharmaceutical Industries Ltd.
11.2.6.1 Company Overview
11.2.6.2 Product Portfolio
11.2.6.3 Demographic Reach and Achievements
11.2.6.4 Certifications
11.2.7 Others
12 Industry Events and Developments
List of Key Figures and Tables
1. Global Glaucoma Therapeutics Market: Key Industry Highlights, 2017 and 2027
2. Global Glaucoma Therapeutics Historical Market: Breakup by Drug Class (USD Billion), 2017-2021
3. Global Glaucoma Therapeutics Market Forecast: Breakup by Drug Class (USD Billion), 2022-2027
4. Global Glaucoma Therapeutics Historical Market: Breakup by Indication (USD Billion), 2017-2021
5. Global Glaucoma Therapeutics Market Forecast: Breakup by Indication (USD Billion), 2022-2027
6. Global Glaucoma Therapeutics Historical Market: Breakup by End-User (USD Billion), 2017-2021
7. Global Glaucoma Therapeutics Market Forecast: Breakup by End-User (USD Billion), 2022-2027
8. Global Glaucoma Therapeutics Historical Market: Breakup by Region (USD Billion), 2017-2021
9. Global Glaucoma Therapeutics Market Forecast: Breakup by Region (USD Billion), 2022-2027
10. North America Glaucoma Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
11. North America Glaucoma Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
12. Europe Glaucoma Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
13. Europe Glaucoma Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
14. Asia Pacific Glaucoma Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
15. Asia Pacific Glaucoma Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
16. Latin America Glaucoma Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
17. Latin America Glaucoma Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
18. Middle East and Africa Glaucoma Therapeutics Historical Market: Breakup by Country (USD Billion), 2017-2021
19. Middle East and Africa Glaucoma Therapeutics Market Forecast: Breakup by Country (USD Billion), 2022-2027
20. Global Glaucoma Therapeutics Market Structure.
Key Questions Answered in the Report
In 2021, the global market for glaucoma therapeutics attained a value of nearly USD 7.24 billion.
The market is projected to grow at a CAGR of 6.20% between 2022 and 2027.
The market is estimated to witness healthy growth in the forecast period of 2022-2027 to reach USD 10.39 billion by 2027.
The major drivers of the market include favourable reimbursement policies, an increase in awareness of glaucoma, rising health consciousness, the invention of unique combination drugs, the introduction of better glaucoma diagnostic techniques and improvements in healthcare infrastructure.
The rising prevalence of glaucoma around the world and the growing geriatric population are the key industry trends propelling the market's growth.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Based on drug class, the market includes prostaglandin analogues, beta-blockers, alpha-adrenergic agonists, carbonic anhydrase inhibitors, and combination drugs, among others.
The various indications of the market are open-angle glaucoma and angle-closure glaucoma, among others.
The end-uses of the market are hospitals, ophthalmic clinics, and ambulatory surgery centres, among others.
The major players in the industry are Aerie Pharmaceuticals Inc., Bausch & Lomb Incorporated, Inotek Pharmaceuticals Corp., SIFI S.p.A, Viatris Inc., and Teva Pharmaceutical Industries Ltd., among others.
Analyst Review
The global glaucoma therapeutics market attained a value of USD 7.24 billion in 2021, driven by the rising prevalence of glaucoma worldwide. Aided by the favourable reimbursement policies and growing geriatric population, the market is expected to witness further growth in the forecast period of 2022-2027, growing at a CAGR of 6.20%. The market is projected to reach USD 10.39 billion by 2027.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on drug class, the market includes prostaglandin analogues, beta-blockers, alpha-adrenergic agonists, carbonic anhydrase inhibitors, and combination drugs, among others. The various indications of the market are open-angle glaucoma and angle-closure glaucoma, among others. The end-uses of the market are hospitals, ophthalmic clinics, and ambulatory surgery centres, among others. The major regional markets for glaucoma therapeutics are North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. The key players in the above market are Aerie Pharmaceuticals Inc., Bausch & Lomb Incorporated, Inotek Pharmaceuticals Corp., SIFI S.p.A, Viatris Inc., and Teva Pharmaceutical Industries Ltd., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1499
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$2699-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateFive User License
$3699-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4699-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
Similar Reports
The global neurological disease treatment market was driven by the rapidly increasing prevalence and incidence of neurological disorders, such as multiple sclerosis, Parkinson's disease, and Alzheimer...
The global hepatic disease treatment market attained a value of nearly USD 21.97 billion, driven by the rise in the prevalence of liver diseases. Aided by the increasing alcohol consumption and growin...
The global autism spectrum disorder therapeutics market attained a value of about USD 3.33 billion in 2021, driven by the rising research and development projects fostered by the government and market...
The global central nervous system treatment market was driven by the increasing incidence of neurological disorders in the historical period. Aided by the launch of new prospective products and pipeli...
The global Duchenne muscular dystrophy (DMD) treatment market attained a value of USD 1.15 million in 2021, driven by the introduction of novel drugs and therapies. Aided by the increased DMD awarenes...
NEWSLETTER